Gilead Announces Results From Interim Analysis Of Phase 3 Trial; Lenacapavir Showed 100% Efficacy For HIV Prevention, Shows Superiority To Daily Truvada
Gilead Announces Results From Interim Analysis Of Phase 3 Trial; Lenacapavir Showed 100% Efficacy For HIV Prevention, Shows Superiority To Daily Truvada
吉利德公司公佈第三期試驗中間分析結果；Lenacapavir表現出100%的艾滋病預防功效，並顯示優於每日Truvada。
Gilead Announces Results From Interim Analysis Of Phase 3 Trial; Lenacapavir Showed 100% Efficacy For HIV Prevention, Shows Superiority To Daily Truvada
吉利德公司公佈第三期試驗中間分析結果；Lenacapavir表現出100%的艾滋病預防功效，並顯示優於每日Truvada。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。